

Oklahoma Health Care Authority

Drug Utilization Review Board

(DUR Board)

Meeting – October 8, 2014 @ 4:00 p.m.

Oklahoma Health Care Authority

4345 N. Lincoln Blvd.

Oklahoma City, Oklahoma 73105

AGENDA

Discussion and Action on the Following Items:

Items to be presented by Dr. Muchmore, Chairman:

1. Call To Order

- A. Roll Call – Dr. Cothran

Items to be presented by Dr. Muchmore, Chairman:

2. Public Comment Forum

- A. Acknowledgment of Speakers and Agenda Items

Items to be presented by Dr. Muchmore, Chairman:

3. Action Item – Approval of DUR Board Meeting Minutes – See Appendix A

- A. September 10, 2014 DUR Minutes – Vote
- B. September 10, 2014 DUR Recommendations Memorandum

Items to be presented by Dr. Holderread, Dr. Muchmore, Chairman:

4. Update on Medication Coverage Authorization Unit/FDA Safety Alerts – See Appendix B

- A. Medication Coverage Activity for September 2014
- B. Pharmacy Help Desk Activity for September 2014
- C. Overview of Safety Alerts

Items to be presented by Dr. Holderread, Dr. Muchmore, Chairman:

5. Action Item – Vote to Prior Authorize Versacloz™ (Clozapine Oral Suspension) – See Appendix C

- A. COP Recommendations

Items to be presented by Dr. Nawaz, Dr. Muchmore, Chairman:

6. Action Item – Vote to Prior Authorize Grastek® (Timothy Grass Pollen Allergen Extract) and Ragwitek™ (Short Ragweed Pollen Allergen Extract) – See Appendix D

- A. COP Recommendations

Items to be presented by Dr. Nawaz, Dr. Muchmore, Chairman:

7. 30-Day Notice to Prior Authorize Sivextro™ (Tedizolid), Dalvance™ (Dalbavancin), and Orbactiv™ (Oritavancin) – See Appendix E

- A. Introduction
- B. Product Summaries
- C. COP Recommendations

Items to be presented by Dr. Adams, Dr. Muchmore, Chairman:

- 8. Annual Review of Antidepressants and 30-Day Notice to Prior Authorize Fetzima[®] (Levomilnacipran), Khedezla[®] (Desvenlafaxine), and Brintellix[®] (Vortioxetine) – See Appendix F**
- A. Current Prior Authorization Criteria
 - B. Utilization of Antidepressants
 - C. Prior Authorization of Antidepressants
 - D. Market News and Updates
 - E. Product Summaries
 - F. COP Recommendations
 - G. Utilization Details of Antidepressants

Items to be presented by Dr. Holderread, Dr. Muchmore, Chairman:

- 9. Annual Review of Biologic Products for the Treatment of Rheumatoid Arthritis, Plaque Psoriasis, and Ankylosing Spondylitis and 30-Day Notice to Prior Authorize Otezla[®] (Apremilast) and Entyvio[™] (Vedolizumab) – See Appendix G**
- A. Current Prior Authorization Criteria
 - B. Utilization of Biologic Products
 - C. Prior Authorization of Biologic Products
 - D. Market News and Updates
 - E. Product Summaries
 - F. COP Recommendations
 - G. Utilization Details of Biologic Products

Items to be presented by Dr. Anderson, Dr. Muchmore, Chairman:

- 10. Action Item – Annual Review of Bladder Control Medications – See Appendix H**
- A. Current Prior Authorization Criteria
 - B. Utilization of Bladder Control Medications
 - C. Prior Authorization of Bladder Control Medications
 - D. Market News and Updates
 - E. COP Recommendations
 - F. Utilization Details of Bladder Control Medications

Items to be presented by Dr. Cothran, Dr. Muchmore, Chairman:

- 11. FDA and DEA Updates – See Appendix I**

Items to be presented by Dr. Cothran, Dr. Muchmore, Chairman:

- 12. Future Business**
- A. Annual Reviews
 - B. New Product Reviews

Items to be presented by Dr. Muchmore, Chairman:

- 13. Adjournment**